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Abstract 
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease presenting highly 
heterogeneous clinical manifestations and multi-systemic involvement. Patients are susceptible 
to relapse and remission, thus making management challenging. Moreover, a considerable 
number of side effects may occur with conventional therapies; therefore, there is clearly a need 
for new therapeutic strategies. Since the pathogenesis of SLE is highly complex, it is far from 
being fully understood. However, greater understanding of the pathways and of the cellular and 
molecular mediators involved in SLE is being achieved. Emerging evidence has allowed the 
development of new biological therapeutic options targeting crucial molecular mediators 
involved in the pathogenesis of SLE. This literature review analyzes the availability of biological 
and target-directed treatments, phase II and III trials, and new therapies that are being developed 
for the treatment of SLE. 
  
1. Introduction [First level heading] 
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by relapses 
and flares with alternating periods of remission. The clinical manifestations are extremely 
heterogeneous with multi-systemic involvement, including symptoms such as fever and malaise, 
as well as dermatological, musculoskeletal, renal, respiratory, cardiovascular, hematological, and 
neurological manifestations [1, 2]. Until recently, the treatment and management of SLE were 
based mainly on non-steroidal anti-inflammatory drugs, glucocorticoids, hydroxychloroquine, 
and immunosuppressive agents [3]. Progress in the treatment of SLE has resulted in a significant 
improvement in prognosis. Nonetheless, SLE management is challenging because of the adverse 
effects of conventional therapies and the occurrence of refractory disease. Thus, the search for 
new therapeutic strategies is relentless. SLE may affect almost any organ during the disease 
course, and several pathogenic pathways drive SLE inflammation in affected tissues. Among 
other processes, the apoptotic process was thoroughly investigated; in particular, the crosslink 
among apoptotic debris-containing autoantigens, innate immunity activation, and the 
maintenance of inflammation has been further elucidated. Genes that breach immune tolerance 
and promote autoantibody production have also been investigated as part of the complex mosaic 
underlying SLE development, as they have been shown to influence innate immune signaling 
and type I interferon (IFN) production, which in turn can generate an influx of effector 
leukocytes, inflammatory mediators, and autoantibodies toward involved organs, such as the 
kidneys. 
Besides, the investigation of monogenic forms of SLE over the years has triggered a better 
understanding of the SLE pathophysiological mechanisms. The findings that homozygous C1q 
deficiency and genetic mutations resulting in low levels of C2 and C4 significantly increase the 
risk of developing SLE are representative examples. 
Given the broad heterogeneity of SLE with regard to genotype and clinical presentation, it is not 
surprising that there is no single drug that is able to improve all manifestations. A better 
understanding of SLE pathogenic mechanisms is well mirrored by some proposed synthetic 
drugs, such as tacrolimus, or biologics, including IFN-α inhibitors and other drugs capable of 
modulating the immune system. 
Attempts to reach a greater understanding of the underlying pathogenesis have resulted in the 
investigation of biological therapies that target crucial molecular mediators of SLE (as 
summarized in Figure 1). Biological therapy is emerging as an increasingly important treatment 
for autoimmune diseases, including SLE. 
 
INSERT FIG. 1 HERE 
 
This literature review analyzes available data on biological and target-directed treatments, on 
phase II and III trials, and on the new therapies that are being developed for the treatment of 
SLE. 
 
2. B-cell target therapies [First level heading] 
To date, the majority of studies have focused on B-cell target therapies [4–7]. Undoubtedly, B 
cells play a crucial role in the pathogenesis of SLE: their loss of tolerance, antigen presentation, 
autoantibody formation, stimulation of cytokine production, and T-cell activation have been 
identified as key players in the pathogenesis of SLE. 
B cells are responsible for stimulating cytokine production, activating T cells, presenting self-
antigens, and producing antibodies [4–7]. Therefore, biological therapies targeting and 
modifying the effects of B cells have been investigated in SLE and other autoimmune diseases. 
Available phase II and III trials of B-cell target therapies are summarized in Table 1. 
 
INSERT TABLE 1 HERE 
 
2.1 Rituximab [Second level heading] 
Rituximab is a chimeric monoclonal antibody (mAb) against CD20 receptors. CD20, or B-
lymphocyte antigen CD20, is extensively expressed on immature, mature, and activated B cells 
but not on stem cells, plasma cells, or pro-B cells. Rituximab selectively binds CD20-positive 
cells and triggers a morphologic cellular change that ultimately results in B-cell depletion for 6 
to 9 months in over 80% of patients [8]. Rituximab is currently licensed for the treatment of non-
Hodgkin’s lymphoma, chronic lymphocytic leukemia, antineutrophil cytoplasmic antibody 
(ANCA)-vasculitis, and rheumatoid arthritis (RA) [9–11]. To date, two randomized controlled 
trials have evaluated the efficacy and safety of rituximab versus placebo in patients with SLE: 
the EXPLORER trial (phase II/III evaluation of rituximab versus placebo in patients with 
moderately to severely active extra-renal SLE) [12] and the LUNAR trial (phase III trial 
evaluation of rituximab versus placebo in patients with class III or IV lupus nephritis) [13]. Both 
trials hypothesized that adding rituximab to the standard of care of corticosteroids and 
immunosuppressants would control SLE activity better than the standard of care alone. 
The EXPLORER trial recruited 257 patients (16–75 years old) with moderate or severe SLE. 
Participants had to fulfill four of the American College of Rheumatology criteria for SLE, 
including positivity for antinuclear antibodies (ANAs), an active disease at screening (defined as 
at least one domain with a British Isles Lupus Assessment Group [BILAG] disease activity index 
A score or at least two domains with a BILAG B), and a stable use of one immunosuppressive 
drug which was continued throughout the study. The effect of placebo versus rituximab in 
achieving and maintaining clinical response at week 52 was the primary endpoint. 
The LUNAR study investigated the safety and efficacy of rituximab at 6 months as compared 
with placebo in addition to high-dose glucocorticoid (GC) and high-dose mycophenolate mofetil 
(MMF) (3g/day) in 144 patients with class III and IV lupus nephritis. The primary endpoint of 
the study was defined as the proportion of patients with complete or partial remission at 12 
months. Complete response was defined as an improvement in serum creatinine from abnormal 
to normal levels or from normal to not more than 115% of baseline normal, a drop in the urine 
protein–creatinine ratio to less than 0.5, and the presence of urine sediment containing fewer than 
five red blood cells in a high-power field without casts at week 52. Neither trial demonstrated 
any significant difference between rituximab and placebo with regard to the primary and 
secondary endpoints. 
Despite the negative results, some points are worth considering. First, biological therapies are 
currently taken into consideration for patients who are refractory to first-line conventional 
immunosuppressive therapies. A high percentage of patients in the two trials (especially in the 
EXPLORER trial) had no history of poor response to conventional therapies, which in itself 
could explain why the primary and secondary endpoints were not met. Furthermore, the efficacy 
of the biological therapy might have been masked by the concomitant high-dose GC therapy (up 
to 1 mg/kg) that was used in both trials. Lastly, the number of patients in the two studies (257 in 
the EXPLORER trial and 144 in the LUNAR trial) was smaller than in trials where the efficacy 
of other biological therapies in SLE was demonstrated. 
The efficacy of rituximab in refractory disease has been reported in several observational studies 
involving SLE patients with renal and non-renal manifestations [14–22]. Moreover, a rituximab-
based protocol (RA schedule) including methylprednisolone (500 mg on days 1 and 15) in the 
induction phase and MMF as a long-term maintenance treatment (Rituxilup trial) was recently 
proposed as a steroid-sparing regimen [16].  
A different approach, initially employed as a rescue therapy in refractory lupus nephritis, has 
been proposed in an effort to minimize the long-term effects of both GCs and the 
immunosuppressive agents that are used for remission maintenance. This approach is based on 
intensified B-lymphocyte depletion consisting of four (weekly) plus two (monthly) doses of 
rituximab (375 mg/sm) in addition to two intravenous administrations of 10 mg/kg 
cyclophosphamide and three pulses of 15 mg/kg methylprednisolone followed by oral 
prednisone tapered to 5 mg/day in 10 weeks without further immunosuppressive maintenance 
therapy [19,22]. Our group, as well as others with considerable experience in this area, see 
rituximab as a therapeutic strategy for patients with refractory SLE although EXPLORER and 
LUNAR failed to achieve their endpoints. 
With regard to safety, overall rituximab has been proven to be generally safe [17–22]. However, 
both early and long-term vigilance for infection post-infusion are important to further balance 
treatment risks and benefits. Besides, although hypogammaglobulinemia can be observed, not all 
patients who develop hypogammaglobulinemia are at increased risk of developing infection after 
B-cell-depleting therapy [20]. A strict surveillance for side effects should be guaranteed, 
especially in the pediatric population with SLE, as infusion reaction and viral infections can 
occur. More rarely, severe cytopenia and central nervous system vasculitis can also be observed 
[21]. 
 
2.2 Belimumab [Second level heading] 
Belimumab is a human immunoglobulin G1λ mAb that inhibits B-cell survival and 
differentiation by blocking the soluble B-lymphocyte stimulator (BLyS) [23]. BLyS is a 
glycoprotein-based cytokine and a member of the tumor necrosis factor (TNF) family. It is an 
essential factor for controlling B-cell survival and is crucial for generating a normal immune 
response [24]. There is sound proof that BLyS is overexpressed in patients with SLE and that its 
expression correlates with variations in disease activity [25]. The role of B lymphocytes in the 
pathogenesis and clinical evolution of SLE supports the potential role of belimumab in the 
treatment of this condition. 
Until 2005, when biological therapies became available, there were few trials on SLE (with the 
exception of lupus nephritis) as compared with those for other autoimmune diseases. Several 
observational studies had demonstrated the efficacy of belimumab for SLE treatment in all ethnic 
groups, including African-Americans [26,27]. However, belimumab was not approved or 
licensed by the US Food and Drug Administration (FDA) (http://www.fda.gov) or the European 
Medicines Agency (http://www.ema.europa.eu) for the treatment of active lupus until 2011 [28]. 
This approval was a cornerstone for the treatment of SLE, since belimumab was the first drug to 
be licensed to treat lupus in over 50 years. 
Phase I and II studies carried out in 2008 and 2009, respectively, provided initial support for its 
use. In total, 519 patients with mild to moderate SLE were recruited for these trials [29,30]. 
Results showed a safety profile for belimumab similar to that observed in the placebo group. 
However, these studies failed to show significant improvement in disease activity as compared 
with the placebo group. Two further trials (BLISS 52 and BLISS 76) were developed [31,32]. 
These international phase III trials enrolled a total of 1,684 patients with SLE (865 patients in the 
BLISS 52 trial and 819 in the BLISS 76 trial) with mild to moderate disease activity. Patients 
with central nervous system (CNS) involvement or renal involvement were excluded. A pooled 
analysis of BLISS 52 and BLISS 76 was performed to evaluate the efficacy and safety in the 
subpopulation of SLE patients with a more-severe disease activity score, defined by the BILAG 
domain score as follows: A (severe disease activity), B (moderate disease activity), or C (mild 
disease activity) in at least one of the domains at baseline. Patients with a SELENA-SLEDAI 
(Safety of Estrogens in Lupus Erythematosus - National Assessment–Systemic Lupus 
Erythematosus Disease Activity Index) score of more than 10, anti-double-stranded DNA (anti-
dsDNA) of at least 30 IU/mL at baseline, or low complement relative to the normal range at 
baseline benefited more from the administration of belimumab than both the placebo arm and the 
SLE patients with a less-severe presentation [33]. Figure 2 summarizes the key results of the 
BLISS 52 and BLISS 76 trials. 
 
INSERT FIG. 2 HERE 
 
A further post-hoc analysis of the BLISS trials focused on the efficacy of belimumab on renal 
parameters in patients with renal involvement and in patients treated with MMF at baseline [34]. 
The pooled analysis population consisted of 1,684 patients. Renal biomarkers showed 
improvement in baseline SELENA-SLEDAI renal involvement at week 52, especially in patients 
receiving MMF therapy. These data suggest that administering belimumab plus standard of care 
may benefit renal outcomes in patients with SLE. 
There is an ongoing BLISS lupus nephritis phase III trial that hopefully will provide information 
regarding the safety and efficacy of belimumab and standard-of-care treatment in patients with 
active lupus nephritis 
(https://clinicaltrials.gov/ct2/show/NCT01639339?term=belimumab+lupus+nephritis&rank=1).  
Belimumab was administered intravenously in all of these trials. The BLISS 52 trial provided us 
with useful information regarding the efficacy and safety of subcutaneously administered 
belimumab. This randomized, double-blind, placebo-controlled trial involving 839 patients with 
active SLE as defined by a SELENA-SLEDAI score of at least 8 showed that subcutaneous 
administration significantly improved the SLE responder index (SRI) and decreased time to 
severe flare as compared with placebo plus standard of care. Furthermore, safety profiles in the 
two arms were similar [35]. 
Several other trials recently assessed the reliability and safety of the novel auto-injector for self-
administration of subcutaneous belimumab 200 mg in patients with SLE [36,37]. The results 
suggest that the bioavailability of subcutaneously administered belimumab is similar to that of 
the intravenous administration and therefore may represent a valid treatment alternative. 
 
2.3 Atacicept [Second level heading] 
Atacicept is a human recombinant fusion protein containing both human IgG and the 
extracellular portion of the B-cell calcium-modulating ligand interactor (TACI) [38]. Atacicept 
inhibits B-cell activation by blocking both BLyS and APRIL (a proliferation-inducing ligand) 
and consequently interrupts their signaling pathways involved in the proliferation of B cells [39–
41]. APRIL is a secreted cytokine produced by a wide range of cells such as monocytes, 
dendritic cells, macrophages, and T cells that are involved in the immune response [42,43]. 
Patients affected by SLE and other autoimmune disorders have higher BLyS and APRIL levels, 
thus suggesting that atacicept may be more efficient because of its dual blockade and its ability 
to target long-living plasma cells in addition to B cells [39,44]. 
Preliminary results from in vivo models and two phase Ib trials showed that atacicept reduces 
both the number of B cells and circulating Ig levels with a minimal rate of adverse events 
[38,45–47]. 
On the basis of these preliminary studies, Ginzler et al. investigated the efficacy and safety of 
atacicept in patients with active lupus nephritis who were treated with high-dose steroids (up to 
60 mg/day) and MMF (3 g/day) for 2 weeks [48]. This trial was terminated early because of 
safety concerns, since three out of six patients developed severe hypogammaglobulinemia and 
severe infections [48]. Whether atacicept was the culprit in these severe side effects remains a 
matter of debate [49]. 
APRIL-SLE was a later double-blind, placebo-controlled trial involving 461 patients with 
moderate to severe SLE who were randomly assigned to receive atacicept 75 or 150 mg 
subcutaneously. The primary endpoint of reducing flares (defined as BILAG A or B) was not 
met. A post-hoc analysis showed a beneficial effect in patients receiving 150 mg atacicept as 
compared with placebo. This preliminary observation is limited as a result of the premature 
discontinuation of the trial because of two infection-related deaths. When the relationship among 
treatment response, baseline biomarker levels, and treatment exposure is assessed, BLyS and 
APRIL may help to identify the patients who are most likely to benefit from atacicept treatment. 
However, the post-hoc analysis demonstrated that the infection rates were similar regardless of 
biomarker levels at baseline or at the time of atacicept exposure [39]. 
 
2.4 Blisibimod [Second level heading] 
A number of studies reported overexpression of B-cell-activating factor (BAFF) in patients with 
SLE and a correlation between its serum levels and disease activity [10]. Blisibimod is a 
subcutaneous BAFF inhibitor. B-cell survival and differentiation are highly dependent on BAFF 
[50]. Its Fc domain is made up of human IgG and four BAFF-binding domain peptides that bind 
soluble and membrane-bound BAFF [51]. 
An initial placebo-controlled phase I trial proved that administering variable doses of blisibimod 
either by single injection or in four weekly doses led to a significant change in B-cell 
subpopulations: a decrease in naïve B cells and an increase in the number of memory B cells 
[29]. In this study, the safety and tolerability profile of blisibimod in patients with SLE were 
comparable with those of placebo. 
A follow-up phase II study, the PEARL-SC study, included 547 patients with SLE [52]. All 
patients were positive for ANAs and anti-dsDNA antibodies and had a SELENA-SLEDAI score 
of at least 6 at baseline. Patients were randomly assigned to either placebo or subcutaneous 
blisibimod at one of three dose levels (100 mg once weekly, 200 mg once weekly, or 200 mg 
every 4 weeks) [52]. High-dose blisibimod (200 mg once weekly) was particularly effective in 
patients with severe SLE, defined as a SELENA-SLEDAI score of at least 10, who were on GCs. 
Overall, the blisibimod group showed higher response rates than the placebo group, thus 
supporting the use of blisibimod as a therapeutic agent for patients with SLE. 
An ongoing, randomized, double-blind, placebo-controlled phase III study—the CHABLIS-
SC1—was presented at the European League against Rheumatism (EULAR) annual meeting in 
2016. The purpose of the study is to evaluate the real impact of adding blisibimod to standard of 
care in patients with active SLE defined as a SELENA-SLEDAI score of at least 10 despite 
stable, ongoing corticosteroid therapy. Results from this trial are still being awaited [53]. 
 
2.5 Tabalumab [Second level heading] 
Tabalumab is a human IgG4 mAb that binds and neutralizes both membrane and soluble BAFF 
[54]. ILLUMINATE-1 and ILLUMINATE-2 are two phase III trials that were designed to 
evaluate the efficacy and safety of administering tabalumab subcutaneously in addition to 
standard of care in patients with active SLE [54,55]. 
ILLUMINATE-1 was a 52-week, multi-center, randomized, double-blind, placebo-controlled 
study that enrolled 1,164 patients with moderate to severe SLE and a SELENA-SLEDAI score of 
at least 6. The primary endpoint (an SRI of 5 at week 52) was not achieved, but the response 
rates in the treatment group were higher than in the placebo group. Whether the high level of 
immunosuppression at baseline actually prevented the primary endpoint from being achieved is a 
valid argument. The secondary endpoints, which were defined as time to first severe SLE flare, 
GC-sparing effects, and changes in fatigue levels, were not met either. However, 
ILLUMINATE-1 results showed a significant decrease in anti-dsDNA levels in the tabalumab 
groups versus placebo as early as week 4 and up to week 52. 
ILLUMINATE-2 was a 52-week, multi-center, randomized, double-blind, placebo-controlled 
study that enrolled 1,124 patients with active SLE [40]. Its primary endpoint, which was defined 
as an SRI of 5, was met at week 52 by 38% of the patients receiving 120 mg tabalumab every 
fortnight in addition to standard of care compared with 27.7% in the placebo group. However, 
although a significant effect on anti-dsDNA reduction and C3 and C4 increase was observed in 
the tabalumab group, ILLUMINATE-2 did not meet its secondary endpoints. Furthermore, 
patients receiving tabalumab showed a decrease in the number of both total B cells and 
immunoglobulins. Tabalumab was more effective at achieving SRI-5 response in serologically 
active patients as compared with non-serologically active ones. 
An additional analysis that focused on the impact on the kidney on the basis of the 
ILLUMINATE-1 and ILLUMINATE-2 trials demonstrated that, compared with placebo, 
tabalumab did not significantly affect the serum creatinine concentration, glomerular filtration 
rate, urine protein–creatinine ratio, or renal flare rates over 1 year in intent-to-treat or intent-to-
treat plus urine protein–creatinine ratio patients. 
 
2.6 Ocrelizumab [Second level heading] 
Ocrelizumab is a second-generation anti-CD20 mAb and, like rituximab, is a B-cell-depleting 
agent. In vitro studies suggest that ocrelizumab may have a safer profile for complement 
activation and immunogenicity than rituximab as well as a lower frequency of both adverse 
infusion reactions and development of neutralizing anti-drug antibodies [56, 57]. 
BEGIN was a phase III randomized study that aimed to evaluate the efficacy and safety of 
ocrelizumab combined with a single, stable-background immunosuppressive medication and a 
corticosteroid regimen in patients with moderately to severely active SLE. The BEGIN study 
was terminated early because of the initial lack of response [58]. 
BELONG is a phase III randomized study. Its aim was to evaluate the efficacy and safety of 
ocrelizumab in patients with class III or IV lupus nephritis [59]. Ocrelizumab was combined with 
either MMF or the Euro-Lupus Nephritis Trial regimen—cyclophosphamide followed by 
azathioprine (AZA) [60]—and a corticosteroid regimen. The BELONG trial was prematurely 
terminated because of the high rates of infection in the ocrelizumab arm. The infection rate was 
higher, especially in patients receiving background immunosuppressive therapy with MMF, 
which suggested a greater immunosuppressive synergy with ocrelizumab. The overall renal 
response among the 223 of the 381 patients who completed the 32-week period of treatment was 
not significantly higher than in the placebo group. 
 
2.7 Epratuzumab [Second level heading] 
Epratuzumab is a fully humanized mAb against CD22, a surface receptor expressed on mature B 
cells [61]. CD22 is involved in B-cell activation and migration and has proven to be significantly 
overexpressed in patients with SLE [62]. 
Two randomized controlled trials of epratuzumab—ALLEVIATE-1 and -2—recruited patients 
with moderately to severely active SLE in order to evaluate health-related quality of life and 
corticosteroid use [63]. Unfortunately, both trials were terminated because of disruption of the 
drug supply. Data analysis of the two studies at 12 weeks showed an increased response rate and 
improvement in the quality of life in the treatment arm albeit without reaching statistical 
significance. 
EMBLEM was a phase IIb trial involving 227 patients with moderately to severely active SLE 
[64]. The response rate of the treatment group was statistically significant as compared with the 
placebo group. A cumulative dose of 2,400 mg of epratuzumab resulted in significant clinical 
improvement. 
EMBODY-1 and -2 were phase III trials that evaluated the efficacy of epratuzumab 600 mg 
every week or 1,200 mg every other week, administered in addition to standard of care [65]. 
Neither study met the primary endpoint. 
 
2.8 Obinutuzumab [Second level heading] 
Obinutuzumab is a humanized, type II anti-CD20 antibody designed to increase direct cell death 
at the expense of reduced complement-dependent cytotoxicity activity [66]. NOBILITY is an 
ongoing phase II trial that aims to evaluate the safety and efficacy of obinutuzumab in addition to 
MMF and corticosteroids in patients with class III or IV lupus nephritis [67]. 
 
2.9 Other regimes [Second level heading] 
Ongoing research is paving the way for the use of synergetic approaches for B-cell 
immunomodulation. The CALIBRATE trial is investigating the effects of rituximab followed by 
maintenance therapy with belimumab in patients with refractory lupus nephritis 
(ClinicalTrials.gov Identifier: NCT02260934). Similarly, the ongoing SYNBIoSe trial 
(ClinicalTrials.gov Identifier: NCT02284984) is investigating the effects of combined therapy 
with anti-CD20 and anti-BLyS on SLE pathogenic autoantibodies. Results are anxiously awaited 
and may represent a cornerstone in the future management of patients with SLE. 
 
3. T-cell target therapies [First level heading] 
Owing to the vast array of autoantibodies that are found, SLE has been typically classified as a 
“B-cell disease”. However, growing evidence supports the role of T cells in the pathogenesis of 
SLE and it is now widely accepted that SLE is a T-cell-driven disease [68,69]. T cells play a 
pivotal role in B-cell maturation, differentiation, antibody production, and class switching. A 
number of phenotypic and functional alterations have been identified in the T cells of patients 
with SLE, alterations likely to trigger the inflammatory response that is seen in these patients. 
New biological T-cell therapies, including cytokine production modulation and T-cell-mediated 
effects on B cells, represent a new therapeutic strategy for patients with SLE. 
 
3.1 Abatacept [Second level heading] 
Abatacept is a fusion protein composed of the Fc region of the immunoglobulin IgG1 fused to 
the extracellular domain of CTLA-4. It binds CD80 and CD86 with higher affinity than CD28 
and blocks the co-stimulatory interaction between T and B lymphocytes, thus leading to 
unsuccessful T-cell activation and thereby preventing B-cell response [70]. 
Merrill et al. [71] carried out a randomized phase IIb trial and enrolled 118 SLE patients with 
polyarthritis, discoid lesions, or pleuritis or pericarditis (or both). The primary and secondary 
endpoints of the study were not met, and after more than 12 months there were no significant 
differences in (BILAG A/B) flare rates between the abatacept and placebo groups. Interestingly, 
post-hoc analyses revealed that severe flares (BILAG A) were less frequent in the abatacept 
group compared with the placebo group [72]. 
Furie et al. [73] conducted a 12-month, randomized, phase II/III, double-blind study that enrolled 
298 SLE patients with active class II or IV lupus nephritis and that added abatacept to MMF and 
GCs. No differences among treatment arms were observed in the time to confirmed complete 
response or in subjects with confirmed complete response following 52 weeks of treatment. 
Although the primary endpoints of these studies were not met, further evidence supports the 
potential efficacy of abatacept in SLE [74] and highlights that its role as a therapeutic alternative 
has yet to be fully defined. 
 
3.2 Laquinimod [Second level heading] 
Laquinimod (5-chloro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-
carboxamide) is an immunomodulatory drug that alters both lymphocytes and 
monocyte/macrophages in murine experimental autoimmune models [75]. It has been used 
successfully in clinical trials in patients with multiple sclerosis with a mild adverse-event profile 
[70]. Laquinimod downregulates pro-inflammatory cytokines—interleukin-6 (IL-6), IL-17, IL-
23, and TNF-α—and increases the production of IL-10, thereby exerting an immunomodulatory 
effect on antigen-presenting cells that target T cells. Its effects lead to immunomodulation in 
favor of T helper 1 over T helper 2 cells [75]. 
In their phase IIa study, Jayne et al. (ClinicalTrials.gov Identifier: NCT01085097)  
(https://clinicaltrials.gov/ct2/show/NCT01085097) evaluated laquinimod in combination with 
MMF and GCs and analyzed its efficacy and safety in 46 patients with active lupus nephritis. 
The preliminary results of the trial seem promising and include improvement in both renal 
function and proteinuria in patients treated with laquinimod, and there was no evidence of any 
increased frequency of side effects. 
 
3.3 Edratide [Second level heading] 
Edratide is a tolerogenic peptide based on the sequence on the first complementarity-determining 
(CDR1) region of anti-DNA mAb (16/6 idiotype) [71]. Preliminary results of the studies were 
promising and showed that edratide downregulates IL-1β, IFN-γ, and IL-10 and upregulates 
transforming growth factor-beta (TGF-β), thus reducing the production of BLyS [41, 76]. A 24-
week phase II trial that enrolled 340 patients with SLE failed to meet its primary endpoints, 
defined as a reduction of both SLEDAI-2K and mean SLEDAI, and therefore the trial was 
prematurely discontinued [77]. Further analysis showed that the secondary endpoint, which was 
an improvement in BILAG scores, was met in the 0.5 mg edratide group and showed a statistical 
difference compared with the placebo arm [77]. 
 
3.4 Rigerimod/Lupuzor [Second level heading] 
Rigerimod, which is also known as Lupuzor, is a peptide derived from a region of the U1-70k 
snRNP protein, a nuclear riboprotein and spliceosome component [78]. The mechanism of action 
of rigerimod is not fully understood, but preliminary studies showed that it acts as an 
immunomodulator by binding major histocompatibility complex (MHC) class II and 
consequently inhibiting T-cell reactivity and restoring immune tolerance [79]. 
The safety and efficacy of rigerimod were assessed in a phase IIa trial that enrolled 20 patients 
with active SLE. Patients were treated with two weekly subcutaneous injections of rigerimod 
(200 µg). A reduction in physician-assessed disease activity was observed, as was a decrease in 
anti-dsDNA levels [80]. A further, randomized, placebo-controlled phase IIb trial confirmed 
these preliminary results. In fact, 136 out of the 149 SLE patients who were enrolled in the trial 
showed a significant reduction in clinical SLEDAI between baseline and week 12 as compared 
with placebo [80]. Further studies are ongoing. 
 
4. Immunoregulatory molecule-targeting therapies [First level heading] 
4.1 Proteasome inhibitors: bortezomib [Second level heading] 
Bortezomib is a proteasome inhibitor that is currently approved for the treatment of multiple 
myeloma. Bortezomib reversibly binds to the 26S proteasome and inhibits its chymotrypsin-like 
activity, resulting in plasma cell depletion [81]. Recently, Alexander et al. [82] investigated the 
safety and efficacy of bortezomib in 12 patients with refractory SLE. Although a subgroup of 
patients showed a decrease in proteinuria, the majority of patients had to discontinue treatment 
because of the high incidence of adverse events. Further studies are needed and must include 
next-generation proteasome inhibitors with a greater tolerability profile. 
 
4.2 Interleukin-6-targeting therapies [Second level heading] 
IL-6 is a pleiotropic cytokine with a wide range of biological activities that plays a crucial role in 
immunoregulation and inflammation. IL-6 promotes B-cell maturation and antibody production 
and contributes to a plethora of immune cell activities, such as cell activation, proliferation, 
differentiation, and cytokine secretion. IL-6 acts in concert with IL-1β and TNF-α to drive 
inflammation and stimulates the differentiation of potent inflammatory Th17 cells and B-cell 
differentiation into plasma cells. In addition, it is key for certain homeostatic mechanisms as well 
as the acute-phase response. 
In vitro and in vivo studies have shown high levels of IL-6 in SLE. A reduction in anti-dsDNA 
antibodies has been observed in murine studies after blocking the IL-6 cascade [83]. 
 
4.2a Tocilizumab [Third level heading] 
Tocilizumab is a humanized mAb directed against IL-6 receptors. Recently, Illei et al. [84] 
enrolled 16 SLE patients with mild to moderate disease activity in an 8-week, phase I dosage-
escalation study to investigate the efficacy and safety of tocilizumab. Disease activity showed 
significant improvement, including a decrease in the SELENA score in eight of the 15 enrolled 
patients and a concomitant, significant decrease in anti-dsDNA titers. However, tocilizumab 
treatment led to dosage-related transient decreases in the absolute neutrophil count, resulting in 
the withdrawal of one of the patients. Further studies are needed to establish the efficacy and 
recommendations of tocilizumab for the treatment of SLE. 
 
4.2b Sirukumab [Third level heading] 
Sirukumab is a humanized mAb that binds to IL-6 and consequently inhibits its biological 
activity. Szepietowski et al. [85] investigated the safety and efficacy of sirukumab in a phase I, 
double-blind, placebo-controlled study involving 15 patients with SLE. Adverse events were 
observed more often in the sirukumab group than in the placebo group (90% versus 80%). 
Sirukumab led to sustained, dose-independent decreases in white blood cell counts, absolute 
neutrophil counts, and platelet counts and minor increases in total cholesterol levels. No 
differences in clinical efficacy were observed between the sirukumab arm and the placebo group. 
A recent multi-center, randomized, double-blind study was set up to assess the efficacy and 
safety of sirukumab in 25 SLE patients with class III or IV active lupus nephritis receiving 
concomitant immunosuppressive therapy [86]. Six patients discontinued the study early, five of 
whom had infection-related adverse events. The median percentage change in proteinuria from 
baseline to week 24 in the sirukumab arm was 0%. In the sirukumab group, 47.6% of patients 
experienced at least one severe adverse event by week 40, most of which were infection related. 
No deaths or malignancies occurred. This study failed to demonstrate an acceptable safety 
profile. 
 4.3 Interferon-alpha-targeting therapies [Second level heading] 
Recent studies have brought to light the role of the activation of the type I IFN pathway in the 
cells of patients with SLE. In fact, type I IFN pathway activation is associated with significant 
clinical manifestations of SLE and the presence of autoantibodies specific for RNA-binding 
proteins [87]. IFN-α-targeting therapies include sifalimumab, rontalizumab, IFN-α kinoid, and 
anifrolumab. 
 
4.3a Sifalimumab [Third level heading] 
Sifalimumab is a human IgG1 mAb that binds IFN-α. Preliminary phase I studies have provided 
encouraging results and have shown that sifalimumab tends to reduce the number of disease 
flares [88,89]. The efficacy and safety of sifalimumab were assessed in a phase IIb, randomized, 
double-blind, placebo-controlled study involving 431 adults with moderately to severely active 
SLE. Patients received monthly intravenous administrations of sifalimumab (200, 600, or 1,200 
mg), and a high percentage of all dosage arms showed index response and clinical improvement 
at week 52 [90]. 
 
4.3b Rontalizumab [Third level heading] 
Rontalizumab is a human IgG1 mAb that binds all known isoforms of human IFN-α. McBride et 
al. [91] ran a preliminary safety, pharmacokinetic profile, and pharmacodynamic effect trial of 
rontalizumab in a cohort of 60 patients with SLE in a dose-escalation study. More recently, 
Kalunian et al. [92] conducted a phase II study in patients with active SLE treated with 750 mg 
intravenous rontalizumab every 4 weeks or placebo and with 300 mg subcutaneous rontalizumab 
every 2 weeks or placebo. Although the primary and secondary endpoints of this trial—reduction 
in disease activity at week 24 by BILAG (primary) and SRI (secondary)—were not met, an 
exploratory analysis showed that rontalizumab treatment was associated with an improvement in 
disease activity, reduced flares, and decreased corticosteroid use in patients with SLE with low 
IFN signature. 
 
4.3c Interferon-alpha kinoid [Third level heading] 
IFN-α kinoid is a drug consisting of inactivated IFN-α coupled with a carrier protein (that is, 
keyhole limpet hemocyanin). IFN-α kinoid is an IFN-α immunogen, which, when appropriately 
adjuvanted, induces transient neutralizing antibodies but no cellular immune response to the 
cytokine and which apparently causes no side effects [93]. Recently, Lauwerys et al. [94] 
examined the safety, immunogenicity, and biologic effects of active immunization with IFN-α 
kinoid in 28 patients with mild to moderate SLE in a randomized, double-blind, placebo-
controlled, phase I/II dose-escalation study. Although IFN-α kinoid was well tolerated, no 
difference in disease activity was reported between groups. 
 
4.3d Anifrolumab [Third level heading] 
Anifrolumab is an antagonist human mAb that targets IFN-α receptor 1 (IFNAR1). Recently, 
Merrill et al. [95] evaluated anifrolumab (300 mg, 1,000 mg every 4 weeks for 1 year) in a 
randomized, phase IIb study that enrolled 305 SLE patients with moderate to severe disease 
activity. Compared with placebo, anifrolumab treatment resulted in higher rates of improvement 
in multiple organs, showing the greatest impact with the administration of 300 mg anifrolumab. 
It is noteworthy that the majority of patients had baseline involvement of the mucocutaneous or 
musculoskeletal domains (or both) of SLEDAI-2K and BILAG. Patients in the 300 mg arm who 
had positive anti-dsDNA or low complement levels (or both) showed lower scores at day 365. 
However, among patients who had normal anti-dsDNA or normal complement levels (or both) at 
baseline, a slightly higher number of patients treated with 300 mg developed new anti-dsDNA or 
hypocomplementemia as compared with baseline. Currently, at least three ongoing phase III 
clinical trials are evaluating the efficacy and safety of anifrolumab versus placebo in patients 
with moderately to severely active autoantibody-positive SLE while receiving standard-of-care 
treatment (ClinicalTrials.gov Identifiers: NCT02446899, NCT02446912, and NCT02794285). 
 
4.4 Interferon-gamma target therapies: AMG811 [Second level heading] 
IFN-γ is a pro-inflammatory cytokine that modulates the immune system, including B cells, T 
cells, and macrophages. Although some of the above-reported studies provide evidence on the 
effect of blocking type I IFNs in SLE, only few have investigated the potential effect of blocking 
type II IFNs. 
AMG 811 is a human IgG1 mAb that selectively targets and neutralizes human IFN-γ. Martin et 
al. [96] enrolled 28 SLE subjects with active lupus nephritis being treated with AMG 811 in 
addition to MMF or AZA. The study reported no significant difference in disease activity, but a 
higher rate of infections was observed in the drug arm. Further studies are needed to assess the 
efficacy of the blockade of type II IFN. 
 
4.5 Abetimus sodium (LJP-394) [Second level heading] 
Abetimus sodium is a tetrameric oligonucleotide that was specifically designed to decrease anti-
dsDNA antibody levels. In fact, abetimus sodium cross-links anti-dsDNA antibody receptors on 
their cell surface, triggering the signal transduction pathways, thus inducing B-cell anergy or 
apoptosis [97]. Preliminary results showed a significant and persistent decrease in anti-dsDNA 
titers in patients with SLE, and there was no increase in adverse events [98]. Based on these 
promising results, a 76-week, double-blind, placebo-controlled study that enrolled 230 SLE 
patients, including patients with lupus nephritis, was set up to investigate LJP-394 efficacy. The 
trial showed a significant decrease in renal flares and lengthened the time to renal flare to 76 
weeks in a subset of patients with high-affinity serum IgG fraction for the DNA epitope of LJP-
394. However, these results were not confirmed in the following phase III studies (ASPEN 
trials), which enrolled 317 and 943 patients with SLE, respectively, and did not meet their 
primary endpoints [99,100]. 
 
4.6 Anti-TNF-α target therapies [Second level heading] 
The role of TNF-α has recently shifted from being a pro-inflammatory cytokine to an 
immunoregulatory molecule that can alter the balance of regulatory T cells [101]. Anti-TNF-α 
target therapies are effective for managing chronic inflammatory disorders such as moderate-to-
severe RA and Crohn’s disease [102–104]. However, their potential role in SLE is still 
controversial, since their use has been associated with new or aggravated forms of autoimmunity 
such as the formation of autoantibodies, including ANAs, anti-dsDNA antibodies, and 
anticardiolipin antibodies [105]. To date, experience on the use of TNF inhibitors, such as 
etanercept and infliximab, is limited in SLE as it has been associated with the induction of anti-
dsDNA; however, anti-TNF antibody could be of potential therapeutic benefit for a selected 
subgroup of patients with SLE (for example, SLE arthritis). Evidence on the use of newer anti-
TNF agents (for example, certolizumab) in patients with SLE is anecdotal [105]. 
 4.6a Etanercept [Third level heading] 
Etanercept is a human TNF receptor p75 Fc fusion protein. It is a dimer of a chimeric protein 
that is genetically engineered by fusing the extracellular ligand-binding domain of human TNF 
receptor-2 to the Fc domain of human IgG1 [106]. Etanercept competitively inhibits TNF 
binding to the cell surface TNF receptor. A randomized, double-blind, placebo-controlled, phase 
II trial recently investigated the potential use of etanercept for the treatment of lupus nephritis 
[107]. The study was terminated early (with just one enrolled subject) because of potential safety 
issues. An ongoing trial is investigating the potential use of intradermal etanercept for the 
treatment of discoid lupus erythematosus [108]. 
 
4.6b Infliximab [Third level heading] 
Infliximab is a human-murine chimeric mAb directed against TNF-α [109]. A recent trial 
investigated the potential use of infliximab in patients with active class V lupus nephritis [110]; 
however, it was terminated early because of failure to recruit patients with membranous lupus 
nephritis who had never been treated with AZA. 
 
4.7 Sphingosine 1-phosphate receptor type 1 agonist (KRP-203) [Second level heading] 
Sphingosine 1-phosphate (SP1) is a pleiotropic lipid mediator that is involved in the regulation of 
a broad spectrum of cellular functions, including proliferation and survival, cytoskeletal 
rearrangements, cell motility, and cytoprotective effects [111, 112]. Following the promising 
preliminary results on the use of KRP-203 (an agonist of SP1) in animal models [113,114], an 
ongoing phase II trial is currently evaluating the safety and efficacy of KRP-203 in patients with 
subacute cutaneous lupus erythematosus (ClinicalTrials.gov Identifier: NCT01294774). 
 
4.8 JAK inhibitors [Second level heading] 
Jaks are tyrosine kinases (Jak1, Jak2, Jak3, and Tyk2) that bind to cell receptor subunits and 
mediate the intracellular signaling initiated by IFN, many interleukins, colony-stimulating 
factors, and hormones such as prolactin, erythropoietin, and growth hormone. Following receptor 
ligation, Jak becomes activated and phosphorylates the latent transcription factors known as 
signal transducers and activators of transcription (STATs). Then STATs, in homodimers or 
heterodimers, translocate into the nucleus where they regulate gene transcription. Mutations of 
Jak or STAT in humans are associated with severe immune dysfunction, revealing the 
fundamental role of this pathway in the induction and regulation of immune responses [115–
119]. Tofacitinib, a small molecule that inhibits Jak3, Jak1, and (to a lesser degree) Jak2, has 
been proven efficacious in RA in phase III trials, and ruxolitinib, which inhibits Jak2, was 
approved by the FDA to treat myelofibrosis [120–122]. Notably, a series of Jak-STAT signaling 
cytokines, especially IFN-Is, IL-10 and IL-6, as well as the hormone prolactin, have been 
implicated in the pathogenesis of SLE [123–126]. In this context, targeting the Jak-STAT 
pathway has emerged as an attractive approach to manage inflammation and auto-immunity in 
SLE. Treatment of lupus-prone mice with JAK2 inhibitors led to prevention or improvement of 
established disease. In MRL/lpr mice, administration of tryphostin AG490 from 12 to 20 weeks 
of age led to a decrease in proteinuria, T-cell and macrophage infiltrates, expression of IFN-γ, 
serum level of dsDNA, and deposition of IgG and C3 in the kidney [127]. A disease prevention 
protocol with another Jak2 inhibitor, CEP-33779, which was started at the age of 8 weeks up to 
21 weeks, prevented the development of nephritis. In addition, administration of CEP-33779 in 
NZB/W F1 mice with established nephritis was proven superior to treatment with 
dexamethasone and cyclophosphamide, resulting in improved survival, reduced proteinuria, 
decreased dsDNA antibodies, and decrease in the autoantibody-producing spleen plasma cells. 
Finally, several cytokines associated with SLE pathogenesis, including IL-12, IL-17A, IL-6, IL-
4, and TNF-α, were also downregulated upon treatment with the Jak2 inhibitor [128]. 
 
5. Future therapeutics [First level heading] 
Several new agents, including an anti-Fcγ-receptor-IIb, Toll-like receptor inhibitors, Jak 
inhibitors, kinase inhibitors specifically targeting spleen tyrosine kinase or phosphoinositide-3-
kinase, and histone deacetylase inhibitors, are currently under investigation as candidate 
therapies for SLE [78]. The rationale for targeting such pathways arose from the growing body 
of evidence investigating monogenic disorders with a lupus-like phenotype. These can be 
organized into physiologic pathways that parallel mechanisms of disease in SLE. Examples 
include genes important for DNA damage repair (for example, TREX1), nucleic acid sensing and 
type I IFN overproduction (for example, STING and TREX1), apoptosis (FASLG), tolerance 
(PRKCD), and clearance of self-antigen (DNASE1L3). Further study of monogenic lupus may 
lead to better genotype/phenotype correlations in SLE. Eventually, the ability to understand 
individual patients according to their genetic profile may allow the development of more targeted 
and personalized approaches to therapy [128–130]. 
 
6. Discussion [First level heading] 
The pathogenesis of SLE is yet to be fully understood, and new biological therapeutic options 
directed against molecular mediators of SLE are being developed now that we are reaching a 
better understanding of the pathogenic pathways and the cellular and molecular mediators 
underlying SLE. Novel biological treatments are rapidly emerging; however, further 
investigational studies are needed. The road to new therapeutic options for the treatment of SLE 
is still challenging. Table 2 summarizes early terminated studies or available investigation on 
drugs whose use in SLE is still speculative at this stage (for example, ustekinumab, a mAb 
directed against the p40 subunit of IL-12/IL-23, has been FDA approved to treat psoriasis and is 
now in trials for SLE). 
 
INSERT TABLE 2 HERE 
 
Assessment studies must be carried out for all novel drugs in order to evaluate their efficacy, 
safety, and immunogenicity profiles. Despite the evident difficulties, phase II and III studies 
should be standardized and efficacy endpoints need to be properly defined and customized to a 
specific SLE population, to specific clinical manifestations, and to organ involvement. Post-
marketing surveillance and registry data are also fundamental when evaluating the long-term 
safety, efficacy, and cost-effectiveness of these novel therapies. Therefore, once they have been 
developed, new biological treatments must undergo a long and expensive process before 
becoming real candidates as SLE primary therapeutic options. 
A careful analysis of failed trials is also highly recommended. Understanding why these studies 
have been unsuccessful is fundamental in order to build better-standardized trial methods and to 
assess whether further studies are warranted to investigate a given drug. 
Standard of care needs to be considered when designing a trial. It is difficult to achieve a 
significant difference between the placebo and drug treatment arms when patients are receiving 
standard-of-care treatment. For example, GC use can increase the response rate in the placebo 
group and thereby influence trial results. Therefore, the exposure to and dosage of GC should be 
limited. In the context of disease activity, the use of GCs should be adjusted and the GC dosage 
should be balanced between arms to minimize introduced bias. Ideally, for mild lupus 
manifestations, GCs should be omitted if possible. Drug trials focusing on patients with dermal 
and musculoskeletal SLE manifestations might demonstrate results of experimental therapy more 
clearly if they omit GC use as a standard of care. However, with the available level of evidence, 
this strategy would be unethical to implement for patients with moderate-to-severe lupus. 
As we acquire a better understanding of SLE pathogenesis, we may be able in the near future to 
correlate clinical manifestations of SLE with specific pathogenic pathways (that is, cellular and 
molecular mediators that could be specifically targeted). Therefore, biological therapies could 
become even more important in SLE management. We hypothesize that, in the future, the 
management of SLE could be tailored to the patient’s specific pathogenic manifestations, genetic 
background, and clinical characteristics by the use of specific biological therapies. 
In conclusion, there is a great deal of enthusiasm regarding the use of new immunomodulatory 
therapies in SLE. Newly available evidence is guiding us toward an understanding of the 
molecular and cellular pathways that are involved in the immunopathogenesis of the disease, 
thus leading the way to new targeted therapies. 
 
Competing interests [First level heading] 
The authors declare that they have no competing interests. 
 Grant information [First level heading] 
The authors declare that no grants were involved in supporting this work. 
  
Figure 1. Targeted biological agents available and in ongoing phase II and III trials of 
systemic lupus erythematosus 
 
Figure 2. Main characteristics of phase III, randomized, placebo-controlled studies (BLISS 
52 and BLISS 76) of belimumab, a monoclonal antibody that inhibits B-lymphocyte 
stimulator, in patients with systemic lupus erythematosus  
Table 1. B-cell targeted biologic therapies in systemic lupus erythematosus (SLE) 
Agent 
(mechanism of 
action) 
Available evidence Ongoing investigation  
Rituximab 
(chimeric anti-
CD20 moAb) 
Primary endpoints were not met in 
LUNAR (SLE with lupus nephritis) 
and EXPLORER (SLE without non-
nephritis) phase III trials. 
 
Promising results from the 
prospective RITUX study, 
investigating RTX as a steroid-
sparing agent in lupus nephritis. 
RITUXILUP trial (phase III)  
RTX as induction therapy followed 
by maintenance MMF 
(ClinicalTrials.gov Identifier: 
NCT01773616). The study has been 
terminated. (Study assessments for 
patients recruited continuing per 
protocol so patients receive a 
minimum of 6 months’ follow-up. No 
safety concerns have been raised.) 
 
RING study (phase III)  
Persistent proteinuria in lupus 
nephritis despite 6 months of 
standard immunosuppression 
(ClinicalTrials.gov Identifier: 
NCT01673295) 
Belimumab Efficacy in the management of the 
musculoskeletal and hematologic 
The BLISS-LN study is investigating 
the value of belimumab as an add-on 
(humanized anti-
BLyS moAB) 
manifestations of SLE (BLISS 52 and 
BLISS 76)  
therapy to standard care in the 
management of lupus nephritis 
(ClinicalTrials.gov Identifier: 
NCT01639339). 
 
CALIBRATE: RTX followed by 
belimumab compared with RTX and 
cyclophosphamide in the management of 
lupus nephritis 
(ClinicalTrials.gov Identifier: 
NCT02260934) 
 
EMBRACE: study of belimumab in 
ethnically diverse groups 
(ClinicalTrials.gov Identifier: 
NCT01632241) 
Blisibimod 
(humanized anti-
BLyS moAb) 
PEARL-SC trial: a phase IIb study 
proved the efficacy, safety, and 
tolerability of blisibimod 
administration in SLE 
(ClinicalTrials.gov Identifier: 
NCT01162681) 
Two trials (CHABLIS-SC1 and 
CHABLIS-SC2) are investigating the 
efficacy and safety of subcutaneous 
blisibimod in addition to standard 
therapy in SLE with and without 
nephritis (ClinicalTrials.gov 
Identifiers: NCT01395745 and 
NCT02074020). 
Atacicept 
(TACI-Ig fusion 
protein) 
ADDRESS II: a phase IIb, multi-
center, randomized, double-blind, 
placebo-controlled, multi-dose, 24-
week study to evaluate the efficacy 
and safety of atacicept in subjects 
with SLE (ClinicalTrials.gov 
Identifier: NCT01972568) 
 
Atacicept phase II/III in generalized 
systemic lupus erythematosus (APRIL-
SLE) (ClinicalTrials.gov Identifier: 
NCT00624338) 
Long-term safety and tolerability of 
atacicept (long-term follow-up of 
patients who participated in 
ADDRESS II) 
Epratuzumab 
(humanized anti-
CD22 moAb) 
Study of epratuzumab versus placebo 
in subjects with moderate-to-severe 
general systemic lupus erythematosus 
(EMBODY 1) (ClinicalTrials.gov 
Identifier: NCT01262365) 
 
Study of epratuzumab versus placebo in 
subjects with moderate-to-severe general 
SLE (EMBODY 2) (ClinicalTrials.gov 
Identifier: NCT01261793) 
Long-term safety and tolerability of 
epratuzumab 
Tabalumab 
(humanized anti-
BAFF moAB) 
ILLUMINATE-1: a phase III, multi-
center, randomized, double-blind, 
placebo-controlled study to evaluate 
the efficacy and safety of 
subcutaneous LY2127399 in patients 
with SLE (ClinicalTrials.gov 
Identifier: NCT01205438) 
 
ILLUMINATE-2: a 52-week, phase 
III, multi-center, randomized, double-
blind, placebo-controlled study. 
Agent was effective at higher study 
dose. 
Not applicable 
Information regarding ongoing clinical trials in SLE was obtained from ClinicalTrials.gov. 
APRIL, a proliferation-inducing ligand; BAFF, B-cell-activating factor; BLyS, B-lymphocyte 
stimulator; CYC, cyclophosphamide; MMF, mycophenolate mofetil; moAB, monoclonal 
antibody; RTX, rituximab; TACI, tumor necrosis factor transmembrane activator and calcium 
modulator and cyclophilin ligand interactor; TNF, tumor necrosis factor.  
Table 2. Other targeted biologic therapies in systemic lupus erythematosus (SLE) 
Agent (mechanism of 
action) 
Available evidence Ongoing investigation  
AMG 557 (inducible T-cell 
co-stimulator ligand, or 
ICOSL) 
Phase 1b, randomized, 
double-blind, placebo-
controlled study, patients 
received AMG 557 210 mg 
(n=10) or placebo (n=10) 
weekly for 3 weeks and then 
every other week for 10 
additional doses in patients 
with SLE and active lupus 
arthritis (ClinicalTrials.gov 
Identifier: NCT01683695) 
N/A 
BG9588 (anti-CD40 ligand 
antibody) 
Twenty-eight patients with 
active proliferative lupus 
nephritis were scheduled to 
receive 20 mg/kg of BG9588 
at biweekly intervals for the 
first three doses and at 
monthly intervals for four 
additional doses. The study 
was terminated prematurely 
N/A 
because of thromboembolic 
events (ClinicalTrials.gov 
Identifier: NCT00001789). 
IL-2 treatment Treatment with low-dose 
recombinant human IL-2 
selectively modulated the 
abundance of regulatory T 
(Treg) cells, follicular helper 
T (T FH) cells, and IL-17-
producing helper T (TH 17) 
cells, but not TH 1 or TH 2 
cells, accompanied by 
marked reductions of disease 
activity in patients with SLE. 
- Low-dose IL-2 for treatment 
of SLE (Charact-IL-2) 
(ClinicalTrials.gov Identifier: 
NCT03312335) 
- Low-dose IL-2 treatment in 
SLE (ClinicalTrials.gov 
Identifier: NCT02084238) 
Induction of regulatory T cells 
by low-dose IL-2 in 
autoimmune and inflammatory 
diseases (ClinicalTrials.gov 
Identifier: NCT01988506) 
Ustekinumab (mAb directed 
against the p40 subunit of IL-
12/IL-23) 
Anecdotal case reports in 
patients with SLE and 
psoriasis 
A phase 2a, efficacy and 
safety study of ustekinumab 
in SLE (ClinicalTrials.gov 
Identifier: NCT02349061) 
IL, interleukin; mAb, monoclonal antibody; N/A, not applicable.  
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